PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2008-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/156802608784535084PMID 18537685
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Differential Interactions of Peroxisome Proliferator-Activated Receptor γ Ligands with Tyr473 Is a Physical Basis for Their Unique Biological Activities

  2008cited by this paper
• Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.

  2008cited by this paper
• Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.

  2007cited by this paper
• Design of a partial PPARdelta agonist.

  2007cited by this paper
• Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.

  2007cited by this paper
• Transcription coactivators for peroxisome proliferator-activated receptors.

  2007cited by this paper
• Evolution of Peroxisome Proliferator-Activated Receptor Agonists

  2007cited by this paper
• Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death

  2007cited by this paper
• The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

  2007cited by this paper
• Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis

  2007cited by this paper
• The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.

  2007cited by this paper
• Partial agonists activate PPARgamma using a helix 12 independent mechanism.

  2007cited by this paper
• Safety issues and prospects for future generations of PPAR modulators.

  2007cited by this paper
• Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.

  2007cited by this paper
• S 26948

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.

  2007cited by this paper
• Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.

  2007cited by this paper
• Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

  2006cited by this paper
• Critical roles of the p160 transcriptional coactivators p/CIP and SRC-1 in energy balance.

  2006cited by this paper
• Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.

  2006cited by this paper
• Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists.

  2006cited by this paper
• Potential importance of leucine in treatment of obesity and the metabolic syndrome.

  2006cited by this paper
• n-3 fatty acids and the metabolic syndrome.

  2006cited by this paper
• Polyunsaturated fatty acids: From diet to binding to ppars and other nuclear receptors

  2006cited by this paper
• From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.

  2006cited by this paper
• Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity

  2006cited by this paper
• Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism.

  2006cited by this paper
• Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.

  2006cited by this paper
• A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.

  2006cited by this paper
• PPARdelta regulates glucose metabolism and insulin sensitivity.

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• A Selective Peroxisome Proliferator-Activated Receptor γ Modulator with Distinct Fat Cell Regulation Properties

  2006cited by this paper
• KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.

  2006cited by this paper
• Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.

  2006cited by this paper
• Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.

  2005cited by this paper
• A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.

  2005cited by this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cited by this paper
• Selective PPARgamma modulators with improved pharmacological profiles.

  2005cited by this paper
• Recent advances in estrogen receptor modulators.

  2005cited by this paper
• Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.

  2005cited by this paper
• Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.

  2005cited by this paper
• Benzoyl 2-methyl indoles as selective PPARgamma modulators.

  2005cited by this paper
• Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

  2005cited by this paper
• Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.

  2005cited by this paper
• GI262570, a Peroxisome Proliferator-Activated Receptor γ Agonist, Changes Electrolytes and Water Reabsorption from the Distal Nephron in Rats

  2005cited by this paper
• Controlling nuclear receptors: the circular logic of cofactor cycles

  2005cited by this paper
• PPARs: therapeutic targets for metabolic disease.

  2005cited by this paper
• Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.

  2005cited by this paper
• Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.

  2005cited by this paper
• Bone is a target for the antidiabetic compound rosiglitazone.

  2004cited by this paper
• PPARs and the complex journey to obesity

  2004cited by this paper
• Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity

  2004cited by this paper
• Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.

  2004cited by this paper
• Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.

  2004cited by this paper
• Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.

  2004cited by this paper
• Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

  2004cited by this paper
• Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

  2004cited by this paper
• Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.

  2004cited by this paper
• Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.

  2003cited by this paper
• PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells.

  2003cited by this paper
• The thyroid hormone receptor-associated protein TRAP220 is required at distinct embryonic stages in placental, cardiac, and hepatic development.

  2003cited by this paper
• Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding.

  2003cited by this paper
• Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.

  2003cited by this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  2003cited by this paper
• PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic

  2003cited by this paper
• Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.

  2003cited by this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.

  2003cited by this paper
• Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

  2003cited by this paper
• Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1

  2003cited by this paper
• Phenylacetic acid derivatives as hPPAR agonists.

  2003cited by this paper
• Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice

  2002cited by this paper
• Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα

  2002cited by this paper
• SRC-1 and TIF2 control energy balance between white and brown adipose tissues.

  2002cited by this paper
• Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis.

  2002cited by this paper
• Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.

  2001cited by this paper
• A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

  2001cited by this paper
• Peroxisome proliferator‐activated receptor (PPAR) modulators: Diabetes and beyond *

  2001cited by this paper
• Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

  2001cited by this paper
• Statin—Fibrate Combination Therapy

  2001cited by this paper
• A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

  2001cited by this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cited by this paper
• Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency.

  2000cited by this paper
• The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development.

  2000cited by this paper
• Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.

  2000cited by this paper
• Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.

  2000cited by this paper
• Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.

  2000cited by this paper
• PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.

  1999cited by this paper
• A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

  1999cited by this paper
• Peroxisome proliferator-activated receptors: nuclear control of metabolism.

  1999cited by this paper
• A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties*

  1998cited by this paper
• Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.

  1998cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• Discovery of Ligands for the Nuclear Peroxisome Proliferator‐activated Receptors

  1996cited by this paper

• Palladium-Catalyzed One-Pot Synthesis of 3‑Arylindoles Based on o‑Iodoaniline with Aryl Hydrazones

  2025cites this paper
• Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders.

  2024cites this paper
• Biochemical, structural characterization and assessing the biological effects of cinnamon nanoparticles

  2024cites this paper
• A novel N-substituted valine derivative with unique PPARy binding properties and biological activities

  2022cites this paper
• Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury.

  2021cites this paper
• Human Placental Transcriptome Reveals Critical Alterations in Inflammation and Energy Metabolism with Fetal Sex Differences in Spontaneous Preterm Birth

  2021cites this paper
• In silico evaluation of naturally isolated triterpene glycosides (TG) from Gymnema sylvestre towards diabetic treatment

  2021cites this paper
• The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.

  2021cites this paper
• A novel N-substituted valine derivative with unique PPARy binding properties and biological activities

  2021cites this paper
• Thyroid and Parathyroid Tumors

  2020cites this paper
• Intrauterine Inflammation Alters the Transcriptome and Metabolome in Placenta

  2020cites this paper
• Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator–activated receptor α

  2020cites this paper
• Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines.

  2019cites this paper
• 2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.

  2019cites this paper
• Novel Series of Benzothiazole-Based Pyrazolidinediones Targeting PPARγ. In Silico Studies, Synthesis and In Vivo Anti-Diabetic Activity.

  2019cites this paper
• Basic mechanisms of the regulation of L‐carnitine status in monogastrics and efficacy of L‐carnitine as a feed additive in pigs and poultry

  2018cites this paper
• A Sterol from Soft Coral Induces Apoptosis and Autophagy in MCF-7 Breast Cancer Cells

  2018cites this paper
• Bilirubin, a Cardiometabolic Signaling Molecule

  2018cites this paper
• In silico molecular docking studies of some phytochemicals against peroxisome-proliferator activated receptor gamma (PPAR-γ)

  2018cites this paper
• Physiology and Pathophysiology of PPARs in the Eye

  2018cites this paper
• Importance of 5/6-aryl substitution on the pharmacological profile of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived PPARγ agonists.

  2017cites this paper
• Cytotoxic effect of a family of peroxisome proliferator‐activated receptor antagonists in colorectal and pancreatic cancer cell lines

  2017cites this paper
• Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptors α antagonists.

  2016cites this paper
• PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration

  2016cites this paper
• In-silico analysis of gymnemagenin from Gymnema sylvestre (Retz.) R.Br. with targets related to diabetes.

  2016cites this paper
• Structural exploration of PPARγ modulators through pharmacophore mapping, fragment-based design, docking, and molecular dynamics simulation analyses

  2016cites this paper
• NOVEL DRUG DISCOVERY FOR DIABETES TYPE-2 BY PHARMACOPHORE, VERTUAL SCREENING AND DOCKING OF PPARγ

  2016cites this paper
• PPARα agonists based on stilbene and its bioisosteres: biological evaluation and docking studies

  2015cites this paper
• Recherche d'un lien entre les diabétiques de type 2 présentant un syndrome métabolique, et les hypothyroïdies, frustes ou avérées, en Aquitaine

  2015cites this paper
• The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes

  2015cites this paper
• The multifaceted factor peroxisome proliferator-activated receptor γ (PPARγ) in metabolism, immunity, and cancer

  2015cites this paper
• The multifaceted factor peroxisome proliferator-activated receptor γ (PPARγ) in metabolism, immunity, and cancer

  2015cites this paper
• Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.

  2015cites this paper
• Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists.

  2015cites this paper
• Titanium-Promoted Acylation of Sulfonamides to N-Acylsulfonamide PPARα Antagonists

  2015cites this paper
• Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.

  2015cites this paper
• Effects of Diisodecyl Phthalate on PPAR:RXR-Dependent Gene Expression Pathways in Sea Bream Hepatocytes.

  2015cites this paper
• Minireview: Challenges and opportunities in development of PPAR agonists.

  2014cites this paper
• Construction of phenoxazine rings containing nitro and sulfonic acid groups leading to phenoxazine-3-sulfonamide derivatives: their evaluation as novel and potential insulin secretagogues

  2014cites this paper
• Discovery of Natural Products that Modulate the Activity of PPARgamma: A Source for New Antidiabetics

  2014cites this paper
• Selective class IIa HDAC inhibitors: myth or reality

  2014cites this paper
• The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma–associated adverse cardiac effects

  2014cites this paper
• Foodinformatics: Applications of Chemical Information to Food Chemistry

  2014influential citation
• Identification of PPARgamma Partial Agonists of Natural Origin (II): In Silico Prediction in Natural Extracts with Known Antidiabetic Activity

  2013cites this paper
• Role of an Indole-Thiazolidine Molecule PPAR Pan-Agonist and COX Inhibitor on Inflammation and Microcirculatory Damage in Acute Gastric Lesions

  2013cites this paper
• LASSO-ing Potential Nuclear Receptor Agonists and Antagonists: A New Computational Method for Database Screening

  2013cites this paper
• 6. Diabetes Drugs

  2013cites this paper
• The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

  2013cites this paper
• Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid.

  2013cites this paper
• Pharmacological and Toxicological Advances in PPAR-Related Medicines

  2012cites this paper
• Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation

  2012cites this paper
• A conserved surface on the ligand binding domain of nuclear receptors for allosteric control.

  2012cites this paper
• PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials

  2012cites this paper
• Nutraceuticals as Ligands of PPARγ

  2012cites this paper
• Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008–present)

  2012cites this paper
• PPAR ACTIVATION BY LT 175 , A NOVEL DUAL PPAR α / γ LIGAND THAT AMELIORATES THE METABOLIC PROFILE AND INSULIN SENSITIVITY IN A MOUSE MODEL OF INSULIN

  2012cites this paper
• Recetores nucleares na terapêutica antidiabética

  2012cites this paper
• Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARα.

  2012cites this paper
• Drug Development for Metabolic Diseases: Past, Present and Future

  2011cites this paper
• Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.

  2011cites this paper
• Lipid‐sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome

  2011cites this paper
• Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.

  2011cites this paper
• Identification of natural products as antidiabetic agents using computer-aided drug design methods

  2011influential citation
• Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods.

  2011cites this paper
• Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.

  2011cites this paper
• Identification and Mechanism of 10-Carbon Fatty Acid as Modulating Ligand of Peroxisome Proliferator-activated Receptors*

  2011cites this paper
• Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity

  2011cites this paper
• Nuclear Receptor Signaling Inhibits HIV-1 Replication in Macrophages through Multiple trans-Repression Mechanisms

  2011cites this paper
• The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance

  2011cites this paper
• Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice

  2011cites this paper
• Minireview: PPARγ as the target of obesogens

  2011cites this paper
• Peroxisome Proliferator-Activated Receptor Delta (PPARD) : Molecular studies of regulation and activation

  2011cites this paper
• HL005--a new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7.

  2011cites this paper
• The PPAR-RXR Transcriptional Complex in the Vasculature Energy in the Balance

  2011cites this paper
• Engineered Nuclear Hormone Receptor-Biosensors for Environmental Monitoring and Early Drug Discovery

  2011cites this paper
• Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

  2010cites this paper
• Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

  2010influential citation
• Non-amyloid Approaches To Alzheimer's Disease

  2010cites this paper
• Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

  2010cites this paper
• A Novel Strategy for Designing the Selective PPAR Agonist by the “Sum of Activity” Model

  2010cites this paper
• Hydroxy monounsaturated fatty acids as agonists for peroxisome proliferator-activated receptors.

  2010cites this paper
• Effects of various bases on acid-catalyzed amination of 2-chloro-5-ethylpyrimidine: synthesis of PPARpan agonist GW693085.

  2010cites this paper
• Application of Molecular Diagnosis Techniques in the Diagnosis and Management of Endocrine Tumors

  2009cites this paper
• Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.

  2009cites this paper
• Molecular Alterations in Hereditary and Sporadic Thyroid and Parathyroid Diseases

  2009cites this paper
• Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists.

  2009cites this paper
• Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.

  2009cites this paper
• Current and emerging strategies for treating dyslipidemia and macrovascular disease.

  2009cites this paper
• Prognostic and Therapeutic Potential of Nuclear Receptors in Head and Neck Squamous Cell Carcinomas

  2009cites this paper
• Understanding nuclear receptors using computational methods.

  2009cites this paper
• The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome.

  2009cites this paper
• Allometric prediction of the human pharmacokinetic parameters for naveglitazar

  2008cites this paper
• Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.

  2008cites this paper
• STRUKTURA, DZIA£ANIE I ROLA RECEPTORA- GAMMA PEROKSYSOMÓW AKTYWOWANEGO

  year unknowncites this paper